Insider Selling: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CAO Sells 4,600 Shares

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) CAO Michael Megna sold 4,600 shares of the company’s stock in a transaction on Thursday, September 3rd. The stock was sold at an average price of $80.30, for a total transaction of $369,380.00. Following the sale, the chief accounting officer directly owned 29,062 shares of the company’s stock, valued at $2,333,678.60. The trade was a 13.67% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kiniksa Pharmaceuticals International Stock Up 0.7%

Shares of Kiniksa Pharmaceuticals International stock traded up $0.58 on Thursday, hitting $80.47. 620,821 shares of the company were exchanged, compared to its average volume of 697,580. The company has a 50-day moving average price of $71.13 and a 200 day moving average price of $56.97. The stock has a market capitalization of $6.28 billion, a price-to-earnings ratio of 82.96 and a beta of 0.09. Kiniksa Pharmaceuticals International, plc has a 1-year low of $35.06 and a 1-year high of $82.94.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its earnings results on Tuesday, July 28th. The company reported $0.30 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.30. Kiniksa Pharmaceuticals International had a return on equity of 13.65% and a net margin of 9.59%.The business had revenue of $243.60 million during the quarter, compared to the consensus estimate of $226.49 million. Research analysts forecast that Kiniksa Pharmaceuticals International, plc will post 1.37 EPS for the current year.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

Hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. raised its stake in Kiniksa Pharmaceuticals International by 1.6% in the 4th quarter. Vanguard Group Inc. now owns 3,112,937 shares of the company’s stock valued at $128,409,000 after purchasing an additional 49,802 shares during the last quarter. UBS Group AG increased its position in shares of Kiniksa Pharmaceuticals International by 56.4% in the fourth quarter. UBS Group AG now owns 77,916 shares of the company’s stock worth $3,214,000 after acquiring an additional 28,099 shares in the last quarter. Inspire Investing LLC acquired a new position in shares of Kiniksa Pharmaceuticals International during the first quarter worth about $1,698,000. BNP Paribas Financial Markets grew its position in Kiniksa Pharmaceuticals International by 27.3% in the fourth quarter. BNP Paribas Financial Markets now owns 831,777 shares of the company’s stock valued at $34,311,000 after acquiring an additional 178,366 shares in the last quarter. Finally, SG Americas Securities LLC lifted its holdings in Kiniksa Pharmaceuticals International by 18.2% in the 1st quarter. SG Americas Securities LLC now owns 640,179 shares of the company’s stock worth $30,825,000 after buying an additional 98,783 shares in the last quarter. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Wedbush lifted their price objective on Kiniksa Pharmaceuticals International from $72.00 to $99.00 and gave the company an “outperform” rating in a research note on Wednesday, July 29th. Citigroup upped their price target on Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the company a “buy” rating in a report on Wednesday, July 29th. JPMorgan Chase & Co. raised their price target on Kiniksa Pharmaceuticals International from $72.00 to $107.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 29th. The Goldman Sachs Group increased their target price on shares of Kiniksa Pharmaceuticals International from $75.00 to $90.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. Finally, Wall Street Zen cut shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research note on Sunday, July 12th. Eight equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $87.38.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.